2-氯-4-(2,2,2-三氟乙氧基)苯酚 | 444341-80-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 2-氯-4-(2,2,2-三氟乙氧基)苯酚
• 英文名称: 2-chloro-4-(2,2,2-trifluoroethoxy)phenol
• CAS: 444341-80-4
• 化学式: C₈H₆ClF₃O₂
• 分子量: 226.583
• InChiKey: OFBKLMDDKYZENG-UHFFFAOYSA-N

物化性质

• 沸点：
  243.4±40.0 °C(Predicted)
• 密度：
  1.445±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2909500000

反应信息

• 作为反应物：
  描述：

  2-氯-4-(2,2,2-三氟乙氧基)苯酚 在 sodium hydroxide 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 12.0h， 生成 (2R)-7-(3-(2-Chloro-4-(2,2,2-trifluoroethoxy)phenoxy)propoxy)-2-ethylchromane-2-carboxylic acid
  参考文献：
  名称：

  (2R)-2-Methylchromane-2-carboxylic acids: Discovery of selective PPARα agonists as hypolipidemic agents

  摘要：

  A SAR study was conducted on chromane-2-carboxylic acid toward selective PPAR alpha agonisim. As a result, highly potent, and selective PPAR alpha agonists were discovered. The optimized compound 43 exhibited robust lowering of total cholesterol levels in hamster and dog animal models. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.028
• 作为产物：
  描述：

  4-苄氧基苯酚 在 palladium on activated charcoal 二异丁胺 、 磺酰氯 、 氢气 、 caesium carbonate 作用下， 生成 2-氯-4-(2,2,2-三氟乙氧基)苯酚
  参考文献：
  名称：

  (2R)-2-Methylchromane-2-carboxylic acids: Discovery of selective PPARα agonists as hypolipidemic agents

  摘要：

  A SAR study was conducted on chromane-2-carboxylic acid toward selective PPAR alpha agonisim. As a result, highly potent, and selective PPAR alpha agonists were discovered. The optimized compound 43 exhibited robust lowering of total cholesterol levels in hamster and dog animal models. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.028

文献信息

• Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
  申请人：——

  公开号：US20020103242A1

  公开（公告）日：2002-08-01

  A class of benzopyrancarboxylic acid derivatives comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.

  一类苯并吡喃羧酸衍生物包括具有强效PPAR alpha和/或gamma激动剂作用的化合物，因此在治疗、控制或预防非胰岛素依赖型糖尿病（NIDDM）、高血糖、血脂异常、高脂血症、高胆固醇血症、高三酸甘油脂血症、动脉粥样硬化、肥胖、血管再狭窄、炎症以及其他PPAR alpha和/或gamma介导的疾病、疾病和疾病状态中具有用处。
• Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
  申请人：Shi Q. Guo

  公开号：US20050228044A1

  公开（公告）日：2005-10-13

  A class of benzodihydrofuran compounds having the structure of formula (I) below and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, such as atherosclerosis.

  一类苯并二氢呋喃化合物，其结构式为（I），以及其药学上可接受的盐，可用作治疗化合物，特别是用于治疗高脂血症、高胆固醇血症、脂质代谢异常和其他脂质紊乱，并延缓或降低与这些疾病相关的病症和后遗症的发生风险，如动脉粥样硬化。
• Novel 2,3-Dihydrobenzofuran-2-carboxylic Acids:  Highly Potent and Subtype-Selective PPARα Agonists with Potent Hypolipidemic Activity
  作者：Guo Q. Shi、James F. Dropinski、Yong Zhang、Conrad Santini、Soumya P. Sahoo、Joel P. Berger、Karen L. MacNaul、Gaochao Zhou、Arun Agrawal、Raul Alvaro、Tian-quan Cai、Melba Hernandez、Samuel D. Wright、David E. Moller、James V. Heck、Peter T. Meinke

  DOI：10.1021/jm050373g

  日期：2005.8.1

  The design and synthesis of a novel class of 2,3-dihydrobenzofuran-2-carboxylic acids as highly potent and subtype-selective PPAR alpha agonists are reported. Systematic study of structure-activity relationships has identified several key structural elements within this class for maintaining the potency and subtype selectivity. Select compounds were evaluated in animal models of dyslipidemia using Syrian hamsters and male Beagle dogs, and all these compounds displayed excellent cholesterol- and triglyceride-lowering activity at dose levels that were much lower than the marketed weak PPAR alpha agonist fenofibrate.
• Design and synthesis of potent and subtype-selective PPARα agonists
  作者：Ranjit C. Desai、Edward Metzger、Conrad Santini、Peter T. Meinke、James V. Heck、Joel P. Berger、Karen L. MacNaul、Tian-quan Cai、Samuel D. Wright、Arun Agrawal、David E. Moller、Soumya P. Sahoo

  DOI：10.1016/j.bmcl.2005.12.022

  日期：2006.3

  Beginning with a moderately potent PPAR gamma agonist 9, a series of potent and highly subtype-selective PPAR alpha agonists was identified through a systematic SAR study. Based on the results of the efficacy studies in the hamster and dog models of dyslipidemia and the desired pharmacokinetic data, the optimized compound 39 was selected for further profiling. (C) 2006 Elsevier Ltd. All rights reserved.
• BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS
  申请人：Merck & Co., Inc.

  公开号：EP1347755A2

  公开（公告）日：2003-10-01